Cygnal Therapeutics Inc., of Cambridge, Mass., was unveiled by Flagship Pioneering this week as a startup developing drugs targeting exoneural biology, an understanding of how nerves and neural signaling drive human health and disease. The company, led by CEO Pearl Huang, is focused initially on cancer and inflammatory disease.